Dl-phenylalanine in depressed patients: an open study

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Depression is a prevalent mood disorder with complex pathophysiology.
• Current antidepressant treatments have variable efficacy and side effect profiles.
• Exploring novel therapeutic agents like amino acid derivatives is crucial.

Purpose of the Study:

• To investigate the antidepressant potential of dl-phenylalanine.
• To assess the efficacy and safety of dl-phenylalanine in patients with depression.
• To identify specific depressive symptoms responsive to dl-phenylalanine.

Main Methods:

• An open-label study involving 20 patients diagnosed with depression (ICD classification).
• Administration of dl-phenylalanine at doses ranging from 75-200 mg/day for 20 days.
• Utilized AMP system, Hamilton depression scale, and von Zerssen self-rating questionnaire for comprehensive assessment.

Main Results:

• 12 out of 20 patients showed significant improvement, with 8 achieving complete remission.
• Core depressive symptoms like depressed mood and psychomotor retardation responded best.
• Anxiety and sleep disturbances showed moderate improvement; hypochondriasis and compulsiveness were unaffected.

Conclusions:

• DL-phenylalanine demonstrates promising antidepressant properties.
• The compound appears particularly effective for core depressive symptoms.
• Further controlled clinical trials are recommended to validate these findings.